Xeris Biopharma (NASDAQ: XERS) revenue
Xeris Biopharma reported revenue of $291.8m for fiscal 2025, 43.7% more than in fiscal 2024 ($203.1m). Since fiscal 2020 its revenue has grown by 1,328.2%, an average growth of 70.2% a year.
Xeris Biopharma has grown its revenue for 5 years in a row, and fiscal 2025 is the highest of its 6 fiscal years on record.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $291.8m | +43.7% | $24.9m | 8.5% |
| 2024 | $203.1m | +23.9% | −$33.6m | −16.6% |
| 2023 | $163.9m | +48.7% | −$44.0m | −26.8% |
| 2022 | $110.2m | +122.3% | −$81.9m | −74.3% |
| 2021 | $49.6m | +142.7% | −$115.2m | −232.2% |
| 2020 | $20.4m | — | −$83.5m | −408.8% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Xeris Biopharma revenue compared with its sector
By revenue for its latest fiscal year, Xeris Biopharma ranks 223rd of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Xeris Biopharma, 43.7%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 221st | Ironwood Pharmaceuticals | $296.2m | −15.7% |
| 222nd | Rigel Pharmaceuticals | $294.3m | 64.1% |
| 223rd | Xeris Biopharma | $291.8m | 43.7% |
| 224th | Aurinia Pharmaceuticals | $283.1m | 20.4% |
| 225th | Adaptive Biotechnologies | $277.0m | 54.8% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Xeris Biopharma
- How much revenue did Xeris Biopharma make in fiscal 2025?
- Xeris Biopharma reported revenue of $291.8m for fiscal 2025, compared with $203.1m in fiscal 2024.
- How much has the revenue of Xeris Biopharma grown?
- Between fiscal 2020 and fiscal 2025 it went from $20.4m to $291.8m: 1,328.2% more, an average growth of 70.2% a year.
- What was the best year for revenue at Xeris Biopharma?
- Of its last 6 fiscal years, fiscal 2025, with $291.8m.
- Where does Xeris Biopharma rank in its sector by revenue?
- It ranks 223rd of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Xeris Biopharma come from?
- From the annual report (Form 10-K) that Xeris Biopharma files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Xeris Biopharma files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Xeris Biopharma: the Xeris Biopharma page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.